Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GOT2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GOT2 Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Ideal for biochemical screens. |
View GOT2 Products |
| Gene Delivery | GOT2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and metabolic flux validation. |
View GOT2 Products |
| Benchmark Ab | Anti-GOT2 Antibody Recombinant positive control for western blot, IHC, and target engagement assays. |
View GOT2 Products |
| Validator | GOT2 siRNA Set For target knockdown verification and phenotypic assay validation. |
View GOT2 Products |
| Related Target A | GOT1 Cytosolic counterpart of GOT2. Essential for selectivity and off-target safety screening. |
View GOT1 Products |
| Related Target B | GLUD1 Synergistic mitochondrial enzyme in glutamine metabolism; co-targeting enhances therapeutic efficacy. |
View GLUD1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling (GOT2 vs. GOT1) | Highly purified human GOT2 and GOT1 ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Mitochondrial target engagement verification | Lentiviral vectors optimized for robust, stable expression of mitochondrial-targeted GOT2. |
| Lack of reliable assay controls | Sequence-verified reference antibodies and validated knockdown siRNA sets included in the assay ecosystem. |
| Assay interference from endotoxins | Strictly controlled endotoxin levels (<1.0 EU/µg) to prevent cellular toxicity in functional metabolic assays. |
Live GOT2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GOT2 therapeutics is intensifying, with major players shifting focus from traditional non-specific metabolic inhibitors to highly selective small-molecule allosteric inhibitors and combination regimens. As first-generation therapies targeting tumor metabolism reach the clinic, the next wave of R&D is targeting the synthetic lethality of GOT2 inhibition in KRAS-mutant cancers, particularly pancreatic ductal adenocarcinoma (PDAC).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Agios Pharmaceuticals, Pfizer, Academic Consortia | Pancreatic Cancer, Colorectal Cancer | Selectivity Assay (Need high-purity GOT2 vs. GOT1 proteins) |
| RNA Therapeutics / siRNA | Alnylam, Alnylam-partnered pipelines | Metabolic Disorders, NASH | In vitro knockdown verification (Need validated siRNA and Lentivirus) |
| Combination Therapies | Deciphera, Novartis | KRAS-mutant Solid Tumors | Target engagement and metabolic profiling (Need stable overexpressing cell lines) |